Both GLP-1 Pills Are Approved Now. Here's How They Differ.

The short version

If needles are what has kept you off a GLP-1, the wait is over. Two pills are approved and prescribable in the US: Wegovy tablets (oral semaglutide), approved 22 December 2025, and Foundayo (orforglipron), approved 1 April 2026³.

One correction before the numbers, because it changes the comparison. The doses that made headlines are not the doses that got approved. Coverage of oral semaglutide quotes 50 mg and about 15%; the approved dose is 25 mg, and its trial result is 13.6%¹. Coverage of orforglipron quotes 36 mg; the maximum dose on the approved label is 17.2 mg². If you are comparing pills against injections using the bigger numbers, you are comparing against products no pharmacy can dispense.

This is educational only and not medical advice.

The two pills, side by side

Wegovy tablets are the same peptide as the injection, formulated to survive the stomach. In its 64-week trial of 307 patients, the 25 mg tablet produced a mean weight change of −13.6% against −2.4% on placebo, a difference of 11.2 percentage points. Nearly six in ten patients lost at least 10% of their body weight, against about one in seven on placebo¹. The catch is the ritual: peptide pills go down on an empty stomach with a small sip of water, and then you wait before anything else passes your lips.

Foundayo is a non-peptide small molecule, which is why it escapes that ritual entirely — once daily, with or without food, swallowed whole². In a 72-week trial of 3,127 patients, the 17.2 mg dose produced −11.1% against −2.1% on placebo². Slightly less weight, considerably less scheduling.

For a working mother that second row may matter more than the first. A pill you have to plan your morning around is a pill you will eventually skip.

How they compare to the injections

The strongest injectables still lead on raw efficiency. Injectable semaglutide 2.4 mg delivered roughly 15% weight loss in its pivotal trial⁴, and tirzepatide reached about 21% at its top dose in SURMOUNT-1⁵.

So the oral tablet at −13.6% is genuinely close to injectable semaglutide, and Foundayo at −11.1% sits below both. That is a real trade, and it is not the only one on the table — a pill that is slightly less potent but actually gets taken beats a stronger injection you dread and postpone. That is a personal calculation, not a ranking.

One caveat on all cross-trial comparisons: these are separate studies with different patients, durations and designs. No head-to-head trial has been run between these four products, so treat the ordering as approximate.

The side effects are the same story

Going oral does not get you out of the GLP-1 adjustment period. In both programs the most common adverse reactions were gastrointestinal — nausea, diarrhea, constipation — mostly mild to moderate and concentrated around dose escalation, the same pattern as the injectables^2,6. If you switch to a pill expecting to dodge the nausea, you will not; the side-effect quick-fix reference applies either way.

Two things specific to Foundayo are worth knowing before you start. It titrates through five steps of at least 30 days each, from 0.8 mg up to 17.2 mg, so reaching the maximum dose takes about five months at the fastest². And if you take an oral contraceptive, its label instructs you to add a barrier method or switch to a non-oral method for 30 days after starting and 30 days after every one of those dose increases². That is a scheduling detail with real consequences, and it is easy to miss on a first read.

What has actually changed

The honest summary of the last year is that "when will there be a pill" stopped being the question. Both exist. The open questions now are the ones that always decide access rather than science: what your plan covers, what the cash price is, and whether a prescriber will write it.

• Approval is not availability. A drug being approved says nothing about whether your insurer covers it or what a month costs out of pocket.
• Ask for the pill by name. "An oral GLP-1" is ambiguous — it now means two different products with different rules, and a compounded preparation is a third thing entirely.
• The dose on your prescription is the number to compare. Not the one in the article you read.

One substitution to avoid

Several telehealth programs sell a compounded oral or dissolving-tablet GLP-1. SynergyRx lists oral semaglutide at $299 a month and oral tirzepatide at $399, and CareBareRX offers oral Rybelsus alongside an oral tirzepatide it describes as available through "compounded or research-based prescribing."

These are not the products above, and that distinction is sharper now than it was a year ago. Wegovy tablets are an approved formulation with published absorption data and an FDA-reviewed label behind them; a compounded sublingual tablet is a pharmacy's own preparation, and how much of the peptide reaches your bloodstream is not established. Paying more per month for the compounded oral version is a trade worth making with your eyes open — and it is now a trade against something you could ask your prescriber for by name.

Effecty prices that trade more gently than most — $245 for a month of its compounded oral semaglutide, or $163 a month if you prepay three — roughly a $50 premium over its injectable rather than the $100 premium SynergyRx charges. Cheaper does not make it the studied product. Effecty's own product pages never name the molecule at all; semaglutide appears only in its help center and the consent form.

BetterMe Rx makes the trade explicit, selling both molecules in both forms and pricing them side by side: $250 a month for oral semaglutide against $205 for the injection. That is the pattern across every program we track — the pill is the premium product, not the budget one. Paying a premium to avoid a needle is a perfectly reasonable choice. Paying it in the belief that you are getting the approved tablet is not.

The efficient takeaway

Both pills are real, approved and prescribable. Wegovy tablets deliver close to injectable semaglutide at 25 mg but demand an empty stomach and a waiting period; Foundayo delivers a little less at 17.2 mg and asks nothing of your schedule. Neither escapes the gastrointestinal adjustment, and the strongest injectable is still ahead of both on raw weight loss. If needle aversion was the only thing standing between you and treatment, that obstacle is gone — bring the specific product name to the appointment and make coverage, not chemistry, the thing you spend the visit on. If you still need a prescriber for it, the best GLP-1 for busy moms board weighs all six Rx-Readiness factors at once rather than ranking on a single strength.